Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Biofrontera (BFRIW) Total Current Liabilities (2020 - 2025)

Biofrontera has reported Total Current Liabilities over the past 6 years, most recently at $11.9 million for Q4 2025.

  • Quarterly results put Total Current Liabilities at $11.9 million for Q4 2025, down 1.05% from a year ago — trailing twelve months through Dec 2025 was $11.9 million (down 1.05% YoY), and the annual figure for FY2025 was $11.9 million, down 1.05%.
  • Total Current Liabilities for Q4 2025 was $11.9 million at Biofrontera, down from $12.6 million in the prior quarter.
  • Over the last five years, Total Current Liabilities for BFRIW hit a ceiling of $29.1 million in Q3 2023 and a floor of $9.3 million in Q2 2024.
  • Median Total Current Liabilities over the past 5 years was $13.8 million (2021), compared with a mean of $15.3 million.
  • Biggest five-year swings in Total Current Liabilities: surged 213.03% in 2021 and later plummeted 62.12% in 2024.
  • Biofrontera's Total Current Liabilities stood at $13.8 million in 2021, then skyrocketed by 51.01% to $20.9 million in 2022, then decreased by 13.43% to $18.1 million in 2023, then crashed by 33.54% to $12.0 million in 2024, then dropped by 1.05% to $11.9 million in 2025.
  • The last three reported values for Total Current Liabilities were $11.9 million (Q4 2025), $12.6 million (Q3 2025), and $19.7 million (Q2 2025) per Business Quant data.